Table 1.
Antiproliferative activity of phenolic-phospholipids against human cancer cell lines.
| Compounds | Acyl Residue | Cell Lines IC50 [μm] | |||||||
|---|---|---|---|---|---|---|---|---|---|
| sn-1 | sn-2 | MV4-11 | A-549 | MCF-7 | LoVo | LoVo/DX | HepG2 | BALB/3T3 | |
| Palmitic acid | - | - | 161 ± 78.9 | 56.4 ± 1.6 | 122.6 ± 63.4 | 42.1 ± 4.6 | 86.3 ± 21.3 | 275.1 ± 85.2 | 60.4 ± 4 |
| DPPC | PA | PA | 178.7 ± 30.3 | 229.7 ± 31.3 | 398.2 ± 1 93.9 | 274.2 ± 17.1 | n.a. | n.a. | 48.8 ± 2.1 |
| 1-PA-LPC | PA | - | 64 ± 0.9 | 62.3 ± 6.5 | 73 ± 4.6 | 52.4 ± 4.3 | 58 ± 3.7 | 282.7 ± 12.5 | 176.2 ± 11.3 |
| 1a (ANISA) | - | - | 264.6 ± 49.2 | n.a. | 483 ± 60.1 | 312.5 ± 29.6 | n.a. | n.a. | n.a. |
| 3a | ANISA | ANISA | 404.3 ± 163.7 ′′ | n.a. | n.a. | 319.2 ± 24.2 ′′ | n.a. | n.a. | n.a. |
| 5a | PA | ANISA | 59.6 ± 6.3 *^′′ | 56.1 ± 1.3 ′′ | 73.1 ± 8.4 *′′ | 52 ± 2.6 *^′′ | 57.7 ± 0.1 ′′ | 289.7 ± 8.2 ′′ | 121 ± 25.9 ′′ |
| 7a | ANISA | - | 21.1 ± 4.9 *^#& | 198.4 ± 14.1 #& | 48.4 ± 2.4 *#& | 43.5 ± 3.2 *^#& | 70.1 ± 2.9 #& | 82.8 ± 9.6 #& | 52.9 ± 8.4 #& |
| 8a | ANISA | PA | 79.5 ± 6.4 *^#′′ | 59.2 ± 0.2 ′′ | 79.4 ± 8.1 *′′ | 59.3 ± 4.6 *^′′ | 59.1 ± 0.9 ′′ | 275.9 ± 12′′ | 201.7 ± 22.4 #′′ |
| 1b (VA) | - | - | 366.3 ± 70.8 | n.a. | 578.6 ± 28.9 | 316.4 ± 30 | n.a. | n.a. | n.a. |
| 3b | VA | VA | 463.7 ± 38.4 ′′ | n.a. | 610.5 ± 5.7 ′′ | 285.5 ± 43.6 ′′ | 120.4 ± 49.9 | 51.4 ± 5.8 ′′ | 354.6 ± 60.2 ′′ |
| 5b | PA | VA | 156.7 ± 66.1 *^′′ | 68.8 ± 1 | 118.6 ± 24.5 *^′′ | 58.8 ± 9.5 *^′′ | 59.9 ± 0.9 ′′ | 274.4 ± 21.7 ^′′ | 251.5 ± 4.3 ^′′ |
| 7b | VA | - | 9.5 ± 2.1 *^#& | 65.4 ± 5 | 20.7 ± 4.3 *^#& | 16.7 ± 1.9 *^#& | 47.8 ± 3.9 #& | 53.1 ± 7.2 #& | 33.2 ± 3.4 ^#& |
| 8b | VA | PA | 164.1 ± 67.1 *^′′ | 82.4 ± 16 | 86.2 ± 8.8 *^′′ | 63.1 ± 6.5 *^′′ | 65.6 ± 0.7 #′′ | 289.6 ± 7.5 ^′′ | 253.1 ± 11.8 ^′′ |
| Cisplatin | 1.3 ± 0.47 | 8.6 ± 0.7 | 8.1 ± 0.03 | 2.56 ± 0.35 | 3.17 ± 0.2 | 2.38 ± 0.64 | 4.2 ± 1.1 | ||
| Doxorubicin | - | - | 0.117 ± 0.012 | 6.53 ± 0.93 | - | - | |||
n.a.—no activity in concentration of 5, 25, 125, 625 μM. IC50—compound concentration leading to 50% inhibition of cell proliferation. Data are presented as mean ± standard deviation (SD) calculated using Prolab-3 system based on Cheburator 0.4 software [32]. *—results within column that are significantly different in comparison to ANISA or VA, respectively; p < 0.05. ^—results within column that are significantly different in comparison to 3a or 3b, respectively; p < 0.05. #—results within column which are significantly different in comparison to 5a or 5b, respectively; p < 0.05. ′′—results within column which are significantly different in comparison to 7a or 7b, respectively; p < 0.05. & — results within column which are significantly different in comparison to 8a or 8b, respectively; p < 0.05. Statistical analysis was performed using STATISTICA version 10 (StatSoft Inc., Palo Alto, CA, USA). t-test was used in the analysis.